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Levels of Haemophilus influenzae type B (Hib) antibody in
Turkey before routine immunization
Cemile SÖNMEZ1, Nilay ÇÖPLÜ1, Demet KURTOĞLU1, Berrin ESEN1,
Annette CROWLEY LUKE2, Lorraine RANSLEY2, Ayşegül GÖZALAN1
Aim: The Haemophilus influenzae type b (Hib) vaccine was introduced into the routine immunization schedule in Turkey
on January 1, 2007. This study investigates the immunity to Hib prior to the introduction of the vaccine.
Materials and methods: Serum samples were collected from healthy volunteers between the ages of 6 months and 50 +
years of age, living in the area of 26 health centers in the Samsun, Antalya, and Diyarbakir provinces during 2000-2001.
In total, 1713 sera were selected for this study, and the younger age groups were given priority (range 0-82). A commercial
ELISA test was used to measure anti-Hib IgG. Hib antibody concentrations of ≤ 0.15, > 0.15 to < 1.0, and ≥ 1.0 μg/mL
were considered as non protective, short-term protection, and long term protection, respectively. The statistical analyses
performed were the chi-square test and logistic regression.
Results: The antibody levels considered non-protective were 58.0%, 35.3%, 28.1%, 19.8%, 18.4%, 15.3%, and 20.6%
among < 5, 5-9, 10-19, 20-29, 30-39, 40-49, and 50 and over age groups, respectively. Protection against Hib infection
increased by age in all 3 provinces.
Conclusion: This study provides important baseline data on anti-Hib antibody levels in Turkey before routine
immunization was introduced, and shows that there is a considerable percentage of subjects with non-protective antibody
levels.
Key words: Haemophilus influenzae type b, antibody, serosurveillance

Türkiye’de rutin immunizasyon öncesi Haemophilus influenzae
tip B (Hib) antikor düzeyleri
Amaç: Türkiye’de 1 Ocak 2007 tarihinden itibaren Haemophilus influenzae tip b (Hib) aşısı rutin immünizasyon
programına dahil edilmiştir. Bu çalışma, aşılama öncesinde Hib’ e karşı bağışıklık durumu hakkında fikir vermektedir.
Yöntem ve gereç: Serum örnekleri 2000-2001 yılları arasında Samsun, Antalya and Diyarbakir illerinde yaşayan 26 sağlık
merkezi tarafından 6 ay ila 50+ yaş arası gönüllü sağlıklı kişiler arasından toplanmıştır. Bu serumlardan 1713’ü bu çalışada
test edilmek üzere seçilmiştir ve genç yaş gruplarına öncelik verilmiştir (0-82 aralığında). Anti Hib IgG antikorlarını
ölçmek için ticari bir ELISA testi kullanılmıştır. Koruyucu olmayan düzey ≤0,15 μg/mL; kısa süreli korunma >0,15-<1,0
μg/mL ve uzun süreli koruyucu titre ≥1,0 μg/mL olarak kabul edilmiştir. İstatistiksel analizler için Ki-kare ve lojistic
regresyon testleri kullanılmıştır.
Bulgular: Yaş grupları <5; 5-9; 10-19; 20-29; 30-39; 40-49; 50 ve üzeri için koruyucu olmayan antikor titreleri sırasıyla
% 58,0; % 35,3; % 28,1; % 19,8; %18,4; % 15,3 ve % 20,6 olarak bulunmuştur. Her üç ilde de Hib infeksiyonuna karşı
korunma yaş ile birlikte artmaktadır.
Sonuç: Bu çalışma rutin aşılama öncesinde Türkiye’de anti-Hib antikor düzeyleri hakkında önemli veri sağlamaktadır ve
ayrıca koruyucu olmayan antikor seviyesine sahip kişilerin önemli bir yüzde oluşturduğunu göstermektedir.
Anahtar sözcükler: Haemophilus influenzae tip b, antikor, serosurveyans
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Introduction
It is estimated there are 3 million cases and 386,000
deaths globally each year associated with severe
Haemophilus influenzae type b (Hib) infection with
the greatest burden in developing countries. Hibassociated diseases in children are primarily
meningitis in children between 3 months and 3 years
of age, and epiglottitis and other invasive diseases,
such as pneumonia, in children 2 to 4 years of age. A
conjugate Hib vaccine, consisting of polyribosylribitol
phosphate (PRP) as an antigen and a protein
immunogen, is now used routinely in more than 90
countries. The use of this efficacious and reliable
vaccine has dramatically reduced the incidence of
Hib-associated disease. In countries that have
achieved high immunization coverage, possibly as a
result of inducing herd immunity, nasopharyngeal
carriage has been diminished, and the transmission
by droplet has decreased (1,2).
A conjugated Hib vaccine was introduced into the
routine immunization schedule of Turkey in January
2007. The vaccine is currently given in conjunction
with DPT-IPV in the 2nd, 3rd, and 4th months, with
a booster dose given between 16 and 24 months of age
(3). This study investigated the immunity to Hib
following natural exposure to the microorganism,
before vaccination. The aim of this study was to
provide baseline data for use in monitoring the impact
of the introduction of the Hib vaccine into the routine
immunization schedule.
Materials and methods
Study group
During the Japanese International Cooperation
Agency (JICA) funded “Infectious Diseases Control
Project in Turkey”, a total of 2465 serum samples were
collected from 3 provinces in Turkey (4). Before
collecting the serum samples, signed consent forms
were collected from all participants. For those under
18 years of age, consent was given by their parents.
Study participants were selected randomly from
healthy subjects living in the areas of 26 health
centers. Epidemiological and demographic data were
collected through a questionnaire-based interview
and subjects were given a basic physical examination
before blood was collected. The age groups were
960

designed for 16 individuals per age group, per survey,
whereas gender and location were equally distributed.
The provinces were selected from different geographic
regions and socioeconomical levels of Turkey. Of
these, 1713 were included in this study to be cost
effective. The distribution of sera selected for this
study gave priority to younger age groups by selecting
74, 79, 84, 77, 81, 85, 75, 65, 75, and 65 serum samples
from 0, 1, 2, 3, 4, 5, 6, 7, 8, and 9 years of age,
respectively. For analysis, age groups were arranged
into 0-4, 5-9, 10-19, 20-29, 30-39, 40-49, and 50 +
year-old group (mean 22.66 ± 20.43, range 0-82) and
the numbers of serum samples tested were 395, 365,
160, 197, 179, 170, and 247, respectively. In this study,
524 (30.6%) of the study participants were from
Diyarbakır, 580 (33.9%) from Samsun, and 609
(35.6%) from Antalya. There was no significant
difference between provinces when age, gender, or
location (rural/urban) were considered (respectively;
P = 0.388, 0.530, 0.121).
Serum samples were collected by obtaining venous
blood, were shipped by cold chain, and kept at -80 °C
until analysed.
Laboratory tests
A commercial ELISA (Immunozym Hib IgG,
Progen Biotechnik GmhB, Heidelberg, Germany) was
used to measure anti-Hib IgG antibodies against
polyribosylribitol-phosphate (PRP) of Haemophilus
influenzae type b in human serum, in Refik Saydam
National Hygiene Center, Communicable Diseases
Research Department. Testing of serum samples was
carried out according to the manufacturer’s
recommendations, and the optical densities of test
reactions read at 405 nm. Standard sera were used to
generate a calibration curve for each test batch, and
this was used to calculate the antibody concentration
from the measured optical density (OD). For quality
control purposes, standard sera, positive high level,
and positive low-level control’s OD were used. The
lowest antibody concentration detectable was
considered to be 0.1 μg/mL.
Hib antibody concentrations ≤ 0.15 μg/mL were
considered as non-protective, > 0.15 μg/mL to < 1.0
μg/mL were considered to indicate short-term
protection, and ≥ 1.0 μg/mL indicated long term
protection (1,5,6). Serum samples were grouped
according to these levels, and 14, 8, and 8 (for a total
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of 30) serum samples were randomly selected from
each level, respectively. These samples were retested
at the Health Protection Agency (HPA), Center for
Emergency Preparedness and Response Laboratory,
UK, using an in-house ELISA.
Statistical analysis
The chi-square and one-way ANOVA test were
used to evaluate statistical differences between the
provinces. The relation between antibody levels and
age, gender, and location was assessed by chi-square
and logistic regression analysis. For logistic regression
(LR) analysis indicative protective (≥1.0 μg/mL) and
non-protective (<1.0 μg/mL) values were accepted as
dependent variables and odds ratios (OR) were
calculated using a 95% confidence interval (CI). SPSS
for Windows 15.00 was used for the analysis.
Results
Results obtained using the commercial ELISA and
the HPA in-house ELISA demonstrated good
correlation, with a correlation coefficient of 0.87.
Distribution of antibody concentrations
The distribution of indicative antibody levels (> =
1; > 0.15 to <1; < = 0.15) according to age in the 0 to
9 year old age groups is shown in the Figure. It was
5.4

12.7

8.3

3.9

observed that both short-term and long-term
protection increased with age, indicating natural
infection before routine vaccine administration. The
antibody levels considered non-protective were
58.0%, 35.3%, 28.1%, 19.8%, 18.4%, 15.3%, and 20.6%
among children under 5 years of age, 5-9, 10-19, 2029, 30-39, 40-49, and 50 and over age groups,
respectively. The protection against Hib infection
increased with age in all 3 provinces. The protective
level (≥1.0 μg/mL) of Hib antibody in Antalya
province (72.1%) was higher than in Diyarbakır
(68.3%) and Samsun (62.8%) with a statistically
significant difference of P = 0.003. The distribution of
antibody concentrations according to age, gender, and
location by protection levels is shown in Table 1. The
older age groups had higher levels of antibody
concentration, especially the participants over 15
years of age, who demonstrated non-protective levels
of antibody in less than 20% of the sera.
Results of the logistic regression analysis are
presented in Table 2. The independent variables were
age, gender, and location, which might influence the
immunity. According to LR analysis, antibody
response to Hib increases with age (Antalya: OR
1.028, 95.0% CI 1.070-1.038; Diyarbakir: OR 1.027,
95.0% CI 1.060-1.038; Samsun: OR 1.041, 95.0% CI
1.030-1.052).

12.3
31.3

32.5

39.6

34.6

30.8
41.2

Percentage

25.2

>=1
>0.15-<1
<=0.15

0

Figure.

1

2

3

4

5-9 10-14 15-19 20-29 30-39 40-49 50+
Age

The distribution of indicative antibody levels (> = 1; > 0.15 to < 1; < =
0.15) according to age between the 0 to 9 years old age groups.
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Table 1. The distribution of Hib antibody levels according to age, gender, and location in Antalya, Diyarbakır, and Samsun; 2000-2001.
Antalya

Diyarbakır

Samsun

n

≤ 0.15*
%

> 0.15-< 1**
%

≥ 1***
%

n

≤ 0.15
%

> 0.15-< 1
%

≥1
%

n

≤ 0.15
%

> 0.15-< 1
%

≥1
%

Age gAAge Group
0-4
5-9
10-19
20-29
30-39
40-4
50+

135
130
52
75
68
64
85

50.4
30.0
19.2
18.7
17.6
18.8
17.6

39.3
44.6
48.1
41.3
48.5
50.0
48.2

10.4
25.4
32.7
40.0
33.8
31.3
34.1

113
113
53
60
51
50
84

50.4
37.2
34.0
26.7
17.6
16.0
19.0

41.6
38.1
39.6
30.0
51.0
38.0
44.0

8.0
24.8
26.4
43.3
31.4
46.0
36.9

147
122
55
62
60
56
78

70.7
39.3
30.9
14.5
20.0
10.7
25.6

21.8
35.2
32.7
50.0
41.7
41.1
53.8

7.5
25.4
36.4
35.5
38.3
48.2
20.5

Gender
Male
Female

279
30

26.5
9.1

45.9
43.9

27.6
27.0

254
270

34.3
29.3

39.0
41.5

26.8
29.3

283
297

36.0
38.4

40.3
33.7

23.7
27.9

Location
Rural
Urban

97
312

7.3
28.5

44.4
45.2

28.3
26.3

287
237

33.1
30.0

36.9
44.3

30.0
25.7

293
287

37.9
36.6

34.5
39.4

27.6
24.0

Total

609

27.9

44.8

27.3

524

31.7

40.3

28.1

580

37.2

36.9

25.9

*non-protective
**short term protection
***long term protection

Table 2. Logistic regression analysis for protective levels (<1μg/mL, ≥1 μg/mL); Antalya, Diyarbakır, and Samsun.
Antalya
OR

95.0% CI

Age

1.028

1.017

Gender
Male*
Female

1
0.894

Residence
Rural*
Urban

1
0.945

Diyarbakır
P

OR

95.0% CI

1.038

0.000**

1.027

1.016

0.620

1.289

0.549

1
1.205

0.657

1.360

0.762

1
1.141

Samsun
P

OR

95.0% CI

P

1.038

0.000**

1.041

1.030

1.052

0.000**

0.825

1.761

0.335

1
0.871

0.609

1.246

0.451

0.779

1.671

0.499

1
1.074

0.751

1.536

0.694

*: Reference group
**: statistically significant

Discussion
The most persuasive way to demonstrate the
effectiveness of a Hib vaccine is to demonstrate a
decrease in the incidence of Hib-associated disease.
In countries where mass vaccination has been
introduced, a reduction of up to 99% in disease
incidence has been demonstrated (10,11). In Turkey,
Hib vaccine was introduced into the routine
childhood immunization schedule in January 2007.
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However, the true incidence of Hib-associated
diseases in Turkey, either currently or immediately
before the introduction of routine immunization, is
not known. The laboratory-based infectious diseases
notification system in Turkey is currently being
improved, but the system is unlikely to improve
quickly enough to provide comprehensive disease
incidence data in the immediate future. An alternative
way to monitor the effectiveness of a vaccine is to
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measure the levels of induced antibodies in vaccinated
individuals, or through serosurveillance activities. To
ensure valid comparisons, baseline data should be
available and include the total population.

2.1% and 47.5%, which may be an important source of
transmission in nurseries and kindergartens,
especially the individuals who are at this age with lowlevel antibody as shown by our study (2,7,8).

This study was designated to provide baseline data
before routine vaccination implementation. Invasive
Haemophilus influenzae type b (Hib) infection is
associated with significant morbidity and mortality in
children under 5 years of age, (10-14) and so we
focused on this age group. According to our results,
children less than 5 years of age were shown to be
susceptible to the infection due to low Hib antibody
levels (Figure). In addition, a percentage of both short
and long term protection levels increased until 10
years of age, which indicates natural infection in the
absence of vaccination, which was also shown by
others (1).

Others have shown that natural immunity may
differ by age, gender, and geographical location, which
is also demonstrated in this study where a statistically
significant difference was found among the 3
provinces (12). The older age groups (>15 years of
age) had higher levels of antibody concentration, with
less than 20% showing non-protective levels of
antibody. On the other hand, in this study, the natural
immunity percentage according to gender was not
found to be statistically significant.

Other studies performed in this country had
shown natural immunity to Hib between 65.3% and
68%, which is higher than our findings (15,16).
However, natural immunity to Hib can be influenced
by geographic distribution, as well as genetic and
socioeconomic factors (15). Studies carried out in
healthy children in Turkey suggest that
nasopharyngeal colonization with Hib varies between

This study has provided baseline data that may be
used for comparison in future surveillance studies in
Turkey, and potentially as comparative data in similar
studies in selected neighbouring countries.
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